Emergent Biosolutions, Inc. (EBS)

From the record

Emergent Biosolutions, Inc.'s filings since 2017 show 3 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2023-11-24); a warning not to rely on past financial statements (8-K item 4.02, the latest 2023-11-16); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2023-11-09) (its current reports).

From the record

Emergent Biosolutions, Inc.'s 10 filed years say what it did: revenue went from $313 million in fiscal 2013 to $743 million in fiscal 2025, up 7.5% a year; it rose in 5 of 9 years; the deepest fall was 58% from fiscal 2021 to fiscal 2025; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Emergent Biosolutions, Inc.'s diluted share count grew about 4.2% a year, and dividends and buybacks returned about 100% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 15 sales (11 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-07 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Emergent Biosolutions, Inc. earned about 10 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 32 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 60 cents per dollar of assets, and net share issuance: its share count grew 7.0% over the year (the filed statements).

From the record

Emergent Biosolutions, Inc.'s standing among 315 graded names in its industry family: revenue of $743 million in fiscal 2025 ranks in the top 15% by size; a net margin of 7.1% ranks in the top 19%; revenue growth of -12.7% a year over the last 3 filed years ranks in the bottom 25% (its annual reports).

From the record

Emergent Biosolutions, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Papa, Joseph C (President and CEO, as filed), filing under that title since 2024-02-29, 2.7 years (bottom 29% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 3.8 years (bottom 23%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 34%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Emergent Biosolutions, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $205 million against debt of $572 million leaves -27.8% of its assets as net cash, bottom 5% of its family; cash from operations less capital spending is 21.1% of revenue (top 11%); a gross margin of 56.1% (bottom 32%); research spending of 7.2% of revenue (bottom 10%) (its annual report).

From the record

Emergent Biosolutions, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -12.7% a year over the last three filed years against 7.5% over all 10, slowing (bottom 26% of its family); the newest year grew -28.8% (bottom 25%); research spending grew -34.4% a year (bottom 11%); capital spending grew -50.8% a year (bottom 20%) (its annual reports). Emergent Biosolutions, Inc. reported 3 product lines in fiscal 2025: Medical Countermeasures MCM Product at $457 million (62%), Commercial Product at $226 million (30%), All Other Revenue at $60 million (8%); 0 of 3 grew against the year before (its annual report).

From the record

Emergent Biosolutions, Inc.'s newest year against its own record: revenue of $743 million in fiscal 2025 came in 26.3% below the $1.0 billion its prior three years' pace pointed to (bottom 28% of its family); net income of $53 million against a prior three-year average of $388 million (top 13%); a net margin of 7.1% against -36.6% before (top 38%) (its annual reports).